Edition:
United States

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

9.60USD
3:59pm EST
Change (% chg)

$-0.91 (-8.66%)
Prev Close
$10.51
Open
$10.56
Day's High
$10.62
Day's Low
$9.56
Volume
68,741
Avg. Vol
52,751
52-wk High
$14.63
52-wk Low
$7.54

Latest Key Developments (Source: Significant Developments)

Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock
Friday, 1 Dec 2017 04:26pm EST 

Dec 1 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION.KARYOPHARM THERAPEUTICS - ON DEC 1, CO ENTERED INTO AMENDMENT NO. 2 TO CONTROLLED EQUITY OFFERING SALES AGREEMENT, DATED DECEMBER 7, 2015 - SEC FILING.  Full Article

Point72 Asset Management L.P. reports 7.3 pct passive stake in Karyopharm Therapeutics Inc as of Nov. 3 - SEC filing‍​
Monday, 6 Nov 2017 04:32pm EST 

Nov 6 (Reuters) - Karyopharm Therapeutics Inc :Point72 Asset Management L.P. reports 7.3 percent passive stake in Karyopharm Therapeutics Inc as of November 3, 2017 - SEC filing‍​.  Full Article

Karyopharm Q3 loss per share $0.65
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm reports third quarter 2017 financial results and highlights recent progress.Q3 loss per share $0.65.Q3 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.Karyopharm Therapeutics Inc - ‍expect to report top-line results of phase 2b storm study by april 2018​.  Full Article

Karyopharm reports positive data from ongoing cancer drug study
Wednesday, 20 Sep 2017 07:00am EDT 

Sept 20 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm announces successful outcome from phase 2 portion of phase 2/3 seal study evaluating selinexor in patients with previously treated advanced dedifferentiated liposarcoma.Karyopharm Therapeutics - ‍phase 3 portion of 2/3 seal​ study commenced; expanded to include North America, Europe, expected to enroll up to 222 patients.Karyopharm Therapeutics Inc - ‍top-line of data expected by end of 2019 for 2/3 seal study​.Karyopharm Therapeutics - ‍FDA has confirmed its acceptance of proposed phase 3 seal study design, including PFS primary endpoint.  Full Article

Karyopharm Therapeutics Q2 loss per share $0.64
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm reports second quarter 2017 financial results and highlights recent progress.Q2 loss per share $0.64.Q2 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.  Full Article

Karyopharm Q1 loss per share $0.71
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm reports first quarter 2017 financial results and highlights recent progress.Q1 loss per share $0.71.Q1 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.  Full Article

Karyopharm and Anivive Lifesciences sign exclusive global license agreement for Verdinexor for Animal Health Applications
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm and Anivive Lifesciences sign exclusive global license agreement for Verdinexor for Animal Health Applications.Karyopharm Therapeutics Inc - Karyopharm to receive $1 million upfront payment.Karyopharm Therapeutics Inc - Karyopharm then eligible to receive up to $43.5 million in future milestones, plus royalties.  Full Article

Karyopharm Therapeutics announces pricing of public offering of common stock
Tuesday, 25 Apr 2017 09:22am EDT 

April 25 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm Therapeutics announces pricing of public offering of common stock.Karyopharm Therapeutics -pricing of a registered underwritten public offering of 3.9 million shares of common stock at price to public of $10.25 per share.  Full Article

Karyopharm Therapeutics announces proposed public offering of common stock
Monday, 24 Apr 2017 04:01pm EDT 

April 24 (Reuters) - Karyopharm Therapeutics Inc : :Karyopharm Therapeutics announces proposed public offering of common stock.Karyopharm Therapeutics Inc says commencing a registered underwritten public offering of $40 million in shares of its common stock.Karyopharm Therapeutics - intends to use proceeds of offering in part to support continued clinical development of selinexor in multiple myeloma.  Full Article

Karyopharm reports interim Phase 2b SADAL data
Tuesday, 4 Apr 2017 01:00pm EDT 

Karyopharm Therapeutics Inc : Karyopharm reports interim Phase 2b SADAL data at the 2017 American Association for Cancer Research annual meeting . 28.6% overall response rate demonstrated with a median duration of greater than seven months . Top-line data from SADAL study expected in mid-2018 . Should data confirm current results, plan to apply for accelerated approval for treatment of relapsed / refractory DLBCL . Amending SADAL study protocol to become single-arm study focusing solely on single-agent selinexor dosed at 60mg twice weekly . SADAL study being amended to reduce 14-week treatment-free period to 8 weeks in patients who achieved at least PR on most recent therapy . Company plans to enroll up to an additional 90 patients to new 60mg single-arm cohort .Patients who were refractory or did not achieve at least a PR on their prior therapy in SADAL study to continue 14-week treatment-free period.  Full Article

BRIEF-Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock

* KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION